NRXP (STOCKS)
NRX Pharmaceuticals, Inc. Common Stock
$2.280000
+0.060000 (+2.70%)
Prev close: $2.220000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jonathan C. Javitt
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $75.56M
- Employees
- —
- P/E (TTM)
- -1.45
- P/B (TTM)
- -4.54
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.01 | $0.00 | -0.0094 | -361.54% |
|
Sep 2025 (Q3)
|
$-0.50 | $-0.09 | -0.4133 | -476.70% |
|
Jun 2025 (Q2)
|
$-0.31 | $-0.21 | -0.1026 | -49.47% |
|
Mar 2025 (Q1)
|
$-0.21 | $-0.31 | +0.0960 | +31.37% |
Financial Statements
| Revenues | $1.23M |
| Benefits Costs and Expenses | $17.45M |
| Cost Of Revenue | $505.00K |
| Costs And Expenses | $17.45M |
| Gross Profit | $720.00K |
| Nonoperating Income/Loss | -$12.40M |
| Operating Expenses | $16.94M |
| Selling, General, and Administrative Expenses | $13.06M |
| Depreciation and Amortization | $70.00K |
| Research and Development | $3.78M |
| Other Operating Expenses | $36.00K |
| Operating Income/Loss | -$16.22M |
| Income/Loss Before Equity Method Investments | -$16.19M |
| Income/Loss From Continuing Operations After Tax | -$28.62M |
| Income/Loss From Continuing Operations Before Tax | -$16.22M |
| Income/Loss From Equity Method Investments | -$35.00K |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$28.62M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$28.62M |
| Net Income/Loss Available To Common Stockholders, Basic | -$28.62M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.34 |
| Basic Average Shares | 21,401,683 |
| Assets | $12.96M |
| Current Assets | $8.89M |
| Noncurrent Assets | $4.06M |
| Fixed Assets | $63.00K |
| Intangible Assets | $925.00K |
| Other Non-current Assets | $3.08M |
| Liabilities | $28.89M |
| Current Liabilities | $28.58M |
| Accounts Payable | $4.27M |
| Wages | $496.00K |
| Other Current Liabilities | $23.81M |
| Noncurrent Liabilities | $315.00K |
| Equity | -$15.94M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$15.94M |
| Liabilities And Equity | $12.96M |
| Net Cash Flow From Operating Activities | -$14.11M |
| Net Cash Flow From Operating Activities, Continuing | -$14.11M |
| Net Cash Flow From Investing Activities | -$2.81M |
| Net Cash Flow From Investing Activities, Continuing | -$2.81M |
| Net Cash Flow From Financing Activities | $23.28M |
| Net Cash Flow From Financing Activities, Continuing | $23.28M |
| Net Cash Flow | $6.35M |
| Net Cash Flow, Continuing | $6.35M |
| Comprehensive Income/Loss | -$28.62M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$28.62M |
| Other Comprehensive Income/Loss | $0.00 |